- After two consecutive below-expectations quarterly results, Doximity Inc DOCS shares surged on Friday after the company reported better-than-expected Q2 FY23 financial results.
- Doximity's Q2 sales climbed 29% Y/Y to $102.19 million, beating the consensus of $100.12 million, with non-GAAP diluted net income per share of $0.17, versus $0.19 a year ago better than the consensus of $0.15.
- The company sees Q3 FY23 sales of $110.7-$111.7 million versus the consensus of $114.9 million.
- Doximity's board also authorized a share buyback of up to $70 million.
- Analyst Reactions:
- Wells Fargo Maintains Overweight on Doximity, Raises Price Target to $44
- Evercore ISI raised the company's price target to $32 from $28.
- Price Action: DOCS shares are up 26.2% at $33.23 on the last check Friday.
© 2024 Benzinga.com. Benzinga does not provide investment advice. All rights reserved.
Benzinga simplifies the market for smarter investing
Trade confidently with insights and alerts from analyst ratings, free reports and breaking news that affects the stocks you care about.
Join Now: Free!
Already a member?Sign in
